Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
206.01
-2.24 (-1.08%)
Nov 18, 2025, 11:52 AM EST - Market open
Krystal Biotech Revenue
Krystal Biotech had revenue of $97.80M in the quarter ending September 30, 2025, with 16.65% growth. This brings the company's revenue in the last twelve months to $373.16M, up 54.51% year-over-year. In the year 2024, Krystal Biotech had annual revenue of $290.52M with 473.02% growth.
Revenue (ttm)
$373.16M
Revenue Growth
+54.51%
P/S Ratio
16.11
Revenue / Employee
$1,356,960
Employees
275
Market Cap
5.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.52M | 239.82M | 473.02% |
| Dec 31, 2023 | 50.70M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KRYS News
- 2 days ago - Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth - Seeking Alpha
- 14 days ago - Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade) - Seeking Alpha
- 15 days ago - Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin - Benzinga
- 2 months ago - Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label - GlobeNewsWire
- 3 months ago - Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update - Seeking Alpha
- 3 months ago - Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer - GlobeNewsWire
- 3 months ago - Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript - Seeking Alpha